Sunrest Lifescience Approves Offer Documents, Receives ISIN for Rights Entitlement
Sunrest Lifescience Limited announced that its Board of Directors, during a meeting held on August 07, 2026, approved several key commercial matters, including the Letter of Offer and related documents for an upcoming equity issuance. The company also confirmed the allotment of an International Securities Identification Number (ISIN) intended for the crediting of Rights Entitlement to eligible shareholders.The Board meeting reviewed and sanctioned all matters on the circulated agenda. Among these approvals was the Letter of Offer, Application Form, and associated documentation. These materials are planned for dispatch to Eligible Equity Shareholders on August 10, 2026, which is set as the Record Date. The consideration of the Letter of Offer builds upon a prior Board meeting held on August 04, 2026.
In a significant development for its stakeholders, Sunrest Lifescience Limited announced that it has been allotted the ISIN INE0PLZ20020. This number is specifically designated for the purpose of crediting Rights Entitlement. The company confirmed that the Rights Entitlements associated with eligible Equity Shareholders will be credited to their respective demat accounts under the assigned ISIN before the Issue opening date.
SUNREST Stock Price Movement
As of 11:44 AM, shares of Sunrest Lifescience Limited are edging higher to ₹41.00, surging 5.13% in live trading today. This strong upward movement is supported by a total traded volume of 4,800 shares so far this session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.